Association of High Expression of Mitochondrial Fission Regulator 2 with Poor Survival of Patients with Esophageal Squamous Cell Carcinoma

다국어 초록 (Multilingual Abstract)

Mitochondrial fission regulator 2 (MTFR2) is associated with mitochondrial fission, while few studies have assessed the associations between MTFR2 expression and clinical characteristics or prognosis of esophageal squamous cell carcinoma (ESCC). In this study, we compared the expression of MTFR2 in 6 ESCC tumors and relative normal tissues by immunohistochemistry (IHC).
To assess the effect of MTFR2 expression on clinicopathologic characteristics and survival, 115 paraffin embedded ESCC tissue samples were assessed by IHC staining. Furthermore, the association between clinicopathological properties and MTFR2 expression in patients with ESCC was examined. The survival analysis was performed using the Cox regression models. We found that MTFR2 expression was significantly increased in ESCC tumors compared with normal esophageal epithelial cells. IHC analysis of 115 paraffin embedded ESCC tumor specimens of the patients showed that the expression of MTFR2 was significantly associated with clinical stage (P < 0.001), tumor classification (P < 0.001), histological grade (P < 0.001), and other clinicopathological characteristics. Both univariate and multivariate analyses showed that MTFR2 expression was inversely correlated with the survival of ESCC patients. In conclusion, the expression of MTFR2 is significantly associated with clinicopathologic characteristics and prognosis of ESCC. Thus, MTFR2 expression could serve as a potentially important prognostic biomarker and clinical target for patients with ESCC.
Key Words MTFR2, Esophageal squamous cell carcinoma, Immunohistochemistry, Prognosis

참고문헌 (Reference)

1 Monticone M, "The nuclear genes Mtfr1 and Dufd1 regulate mitochondrial dynamic and cellular respiration" 225 : 767-776, 2010

2 Liu X, "The MPS1 family of protein kinases" 81 : 561-585, 2012

3 Hsieh MS, "The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma" 7 : 36956-36970, 2016

4 Wang J, "Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma" 9 : 3081-3088, 2017

5 Maire V, "TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer" 8 : e63712-, 2013

6 Nath S, "Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10" 286 : 15666-15677, 2011

7 Zhong L, "Research progress on radiotherapy of esophageal carcinoma" 43 : 527-530, 2016

8 Lu W, "Overexpression of MTFR2 predicts poor prognosis of breast cancer" 12 : 11095-11102, 2020

9 Li J, "Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-κB Pathway" 176 : 699-709, 2010

10 Han X, "Nimotuzumab combined with chemotherapy is a promising treatment for locally advanced and metastatic esophageal cancer" 23 : 412-418, 2017

11 Jelluma N, "Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment" 132 : 233-246, 2008

12 Rahman J, "Mitochondrial medicine in the omics era" 391 : 2560-2574, 2018

13 Lu G, "Mitochondrial fission regulator 2(MTFR2)promotes growth, migration, invasion and tumour progression in breast cancer cells" 11 : 10203-10219, 2019

14 Sabharwal SS, "Mitochondrial ROS in cancer : initiators, amplifiers or an Achilles’ heel" 14 : 709-721, 2014

15 Wang W, "MTFR2 promotes the proliferation, migration, and invasion of oral squamous carcinoma by switching OXPHOS to glycolysis" 10 : 858-, 2020

16 Kaistha BP, "Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells" 111 : 1780-1787, 2014

17 Monticone M, "Impaired expression of genes coding for reactive oxygen species scavenging enzymes in testes of Mtfr1/Chppr-deficient mice" 134 : 483-492, 2007

18 Perrotta I, "Immunohistochemical analysis of the ubiquitin-conjugating enzyme UbcH10 in lung cancer : a useful tool for diagnosis and therapy" 60 : 359-365, 2012

19 Daniel J, "High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells" 108 : 5384-5389, 2011

20 Torre LA, "Global cancer statistics, 2012" 65 : 87-108, 2015

21 Chen C, "Evaluation of clinical value and potential mechanism of MTFR2in lung adenocarcinoma via bioinformatics" 21 : 619-, 2021

22 Ren QG, "Evaluation of HO-1 expression, cellular ROS production, cellular proliferation and cellular apoptosis in human esophageal squamous cell carcinoma tumors and cell lines" 35 : 2270-2276, 2016

23 Andl CD, "Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo" 278 : 1824-1830, 2003

24 Lin Y, "Epidemiology of esophageal cancer in Japan and China" 23 : 233-242, 2013

25 Tonachini L, "Chondrocyte protein with a poly-proline region(CHPPR)is a novel mitochondrial protein and promotes mitochondrial fission" 201 : 470-482, 2004

26 Kleinberg L, "Chemoradiation in the management of esophageal cancer" 25 : 4110-4117, 2007

27 Hudler P, "Association between polymorphisms in segregation genes BUB1B and TTK and gastric cancer risk" 50 : 297-307, 2016

28 Yu DL, "Acyl-CoA dehydrogenase long chain expression is associated with esophageal squamous cell carcinoma progression and poor prognosis" 11 : 7643-7653, 2018

29 Dastsooz H, "A comprehensive bioinformatics analysis of UBE2C in cancers" 20 : 2228-, 2019